Evaluation of HIV-1 integrase variability by combining computational and probabilistic approaches.


Journal

Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
ISSN: 1567-7257
Titre abrégé: Infect Genet Evol
Pays: Netherlands
ID NLM: 101084138

Informations de publication

Date de publication:
07 2022
Historique:
received: 16 12 2021
revised: 24 03 2022
accepted: 28 04 2022
pubmed: 6 5 2022
medline: 1 6 2022
entrez: 5 5 2022
Statut: ppublish

Résumé

This study aimed at updating previous data on HIV-1 integrase variability, by using effective bioinformatics methods combining different statistical instruments from simple entropy and mutation rate to more specific approaches such as Hellinger distance. A total of 2133 HIV-1 integrase sequences were analyzed in: i) 1460 samples from drug-naïve [DN] individuals; ii) 386 samples from drug-experienced but INI-naïve [IN] individuals; iii) 287 samples from INI-experienced [IE] individuals. Within the three groups, 76 amino acid positions were highly conserved (≤0.2% variation, Hellinger distance: <0.25%), with 35 fully invariant positions; while, 80 positions were conserved (>0.2% to <1% variation, Hellinger distance: <1%). The H12-H16-C40-C43 and D64-D116-E152 motifs were all well conserved. Some residues were affected by dramatic changes in their mutation distributions, especially between DN and IE samples (Hellinger distance ≥1%). In particular, 15 positions (D6, S24, V31, S39, L74, A91, S119, T122, T124, T125, V126, K160, N222, S230, C280) showed a significant decrease of mutation rate in IN and/or IE samples compared to DN samples. Conversely, 8 positions showed significantly higher mutation rate in samples from treated individuals (IN and/or IE) compared to DN. Some of these positions, such as E92, T97, G140, Y143, Q148 and N155, were already known to be associated with resistance to integrase inhibitors; other positions including S24, M154, V165 and D270 are not yet documented to be associated with resistance. Our study confirms the high conservation of HIV-1 integrase and identified highly invariant positions using robust and innovative methods. The role of novel mutations located in the critical region of HIV-1 integrase deserves further investigation.

Identifiants

pubmed: 35513162
pii: S1567-1348(22)00091-0
doi: 10.1016/j.meegid.2022.105294
pii:
doi:

Substances chimiques

HIV Integrase Inhibitors 0
HIV Integrase EC 2.7.7.-
p31 integrase protein, Human immunodeficiency virus 1 YY6481J2FF

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105294

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Davide Vergni (D)

Istituto per le Applicazioni del Calcolo "Mauro Picone" - CNR, Rome, Italy. Electronic address: davide.vergni@cnr.it.

Daniele Santoni (D)

Istituto di Analisi dei Sistemi ed. Informatica "Antonio Ruberti" - CNR, Rome, Italy.

Yagai Bouba (Y)

Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management (CIRCB), Yaoundé, Cameroon; Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Saverio Lemme (S)

Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Lavinia Fabeni (L)

Laboratory of Virology, IRCCS, National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy.

Luca Carioti (L)

Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Ada Bertoli (A)

Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy; Laboratory of Virology, University Hospital "Tor Vergata", Rome, Italy.

William Gennari (W)

Microbiology and Virology Unit, University Hospital, University of Modena and Reggio Emilia, Modena, Italy.

Federica Forbici (F)

Laboratory of Virology, IRCCS, National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy.

Carlo Federico Perno (CF)

Multimodal Laboratory Research Department, Children Hospital Bambino Gesù, IRCCS, Rome, Italy.

Roberta Gagliardini (R)

HIV/AIDS Department, IRCCS, National Institute for Infectious Diseases "Lazzaro Spallanzani", Rome, Italy.

Francesca Ceccherini-Silberstein (F)

Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy.

Maria Mercedes Santoro (MM)

Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy. Electronic address: maria.santoro@uniroma2.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH